MQS Management LLC Purchases Shares of 10,201 Bausch Health Companies Inc. (NYSE:BHC)

MQS Management LLC acquired a new position in shares of Bausch Health Companies Inc. (NYSE:BHC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,201 shares of the company’s stock, valued at approximately $71,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new stake in Bausch Health Companies during the 4th quarter valued at approximately $31,121,000. Hillsdale Investment Management Inc. boosted its stake in shares of Bausch Health Companies by 1,050.8% in the 1st quarter. Hillsdale Investment Management Inc. now owns 3,409,383 shares of the company’s stock valued at $36,135,000 after purchasing an additional 3,113,123 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Bausch Health Companies by 3,080.9% during the first quarter. SG Americas Securities LLC now owns 2,200,526 shares of the company’s stock worth $23,348,000 after buying an additional 2,131,347 shares during the period. Crestline Management LP bought a new position in Bausch Health Companies during the fourth quarter worth $16,040,000. Finally, Hein Park Capital Management LP lifted its holdings in Bausch Health Companies by 56.9% in the first quarter. Hein Park Capital Management LP now owns 1,653,579 shares of the company’s stock valued at $17,544,000 after buying an additional 600,000 shares during the period. 78.65% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the transaction, the executive vice president now owns 435,198 shares of the company’s stock, valued at $2,702,579.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.12% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Scotiabank decreased their price target on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a report on Friday, August 2nd. Raymond James began coverage on Bausch Health Companies in a report on Wednesday, July 10th. They issued a “market perform” rating and a $8.00 target price for the company. Jefferies Financial Group cut their price target on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. StockNews.com lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Tuesday, September 17th. Finally, Truist Financial cut their target price on shares of Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.33.

Bausch Health Companies Stock Down 1.8 %

Shares of BHC opened at $8.03 on Friday. The business’s fifty day moving average is $6.28 and its 200 day moving average is $7.33. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $11.46. The stock has a market cap of $2.90 billion, a P/E ratio of -6.48 and a beta of 0.75.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same period last year, the firm earned $0.81 earnings per share. On average, analysts expect that Bausch Health Companies Inc. will post 3.61 EPS for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.